A total of 110 SCLC patients receiving first-line PD-1/PD-L1 inhibitors were identified, of which, four patients received only one dose of PD-1/PD-L1 inhibitors, and six patients had no pretreatment blood test results (Figure 1). This evidence concerns the gene PDCD1 and small cell lung carcinoma.